Daniel P. Dever

4.7k total citations · 3 hit papers
28 papers, 2.9k citations indexed

About

Daniel P. Dever is a scholar working on Molecular Biology, Genetics and Genetics. According to data from OpenAlex, Daniel P. Dever has authored 28 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Molecular Biology, 7 papers in Genetics and 7 papers in Genetics. Recurrent topics in Daniel P. Dever's work include CRISPR and Genetic Engineering (19 papers), Hemoglobinopathies and Related Disorders (7 papers) and Toxic Organic Pollutants Impact (5 papers). Daniel P. Dever is often cited by papers focused on CRISPR and Genetic Engineering (19 papers), Hemoglobinopathies and Related Disorders (7 papers) and Toxic Organic Pollutants Impact (5 papers). Daniel P. Dever collaborates with scholars based in United States, India and Spain. Daniel P. Dever's co-authors include Matthew H. Porteus, Rasmus O. Bak, Joab Camarena, Mara Pavel-Dinu, Kenneth I. Weinberg, Sruthi Mantri, Natalia Gomez‐Ospina, Christopher A. Vakulskas, Mark A. Behlke and Michael A. Collingwood and has published in prestigious journals such as Nature, Nucleic Acids Research and Nature Medicine.

In The Last Decade

Daniel P. Dever

27 papers receiving 2.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Identification of preexisting adaptive immunity to Cas9 proteins in humans

2019 665 citations Carsten T. Charlesworth, Daniel P. Dever et al. Nature Medicine profile →
CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells

2016 641 citations Daniel P. Dever, Rasmus O. Bak et al. Nature profile →
A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells

2018 541 citations Christopher A. Vakulskas, Daniel P. Dever et al. Nature Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daniel P. Dever United States	17	2.4k	947	424	307	251	28	2.9k
Kendell Clement United States	23	2.8k 1.2×	680 0.7×	171 0.4×	124 0.4×	121 0.5×	41	3.0k
Izuho Hatada Japan	32	2.9k 1.2×	879 0.9×	225 0.5×	107 0.3×	124 0.5×	88	3.5k
Xavier M. Anguela United States	17	1.7k 0.7×	1.3k 1.4×	476 1.1×	101 0.3×	62 0.2×	31	2.2k
Virginia Haurigot Spain	24	1.3k 0.5×	989 1.0×	239 0.6×	158 0.5×	41 0.2×	35	2.0k
Andreas Reik United States	20	2.5k 1.0×	794 0.8×	706 1.7×	361 1.2×	44 0.2×	47	3.2k
Russell C. DeKelver United States	15	2.0k 0.8×	673 0.7×	179 0.4×	84 0.3×	71 0.3×	29	2.2k
Henriette O’Geen United States	28	2.4k 1.0×	527 0.6×	118 0.3×	91 0.3×	43 0.2×	43	2.7k
Lingqian Wu China	24	1.2k 0.5×	865 0.9×	124 0.3×	170 0.6×	23 0.1×	186	2.4k
Jonathan D. Chesnut United States	22	2.1k 0.9×	492 0.5×	170 0.4×	90 0.3×	77 0.3×	38	2.4k
Anthony D’Ippolito United States	10	2.3k 1.0×	484 0.5×	166 0.4×	30 0.1×	162 0.6×	20	2.6k

Countries citing papers authored by Daniel P. Dever

Since Specialization

Citations

This map shows the geographic impact of Daniel P. Dever's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel P. Dever with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel P. Dever more than expected).

Fields of papers citing papers by Daniel P. Dever

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel P. Dever. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel P. Dever. The network helps show where Daniel P. Dever may publish in the future.

Co-authorship network of co-authors of Daniel P. Dever

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel P. Dever. A scholar is included among the top collaborators of Daniel P. Dever based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel P. Dever. Daniel P. Dever is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Baik, Ron, M. Kyle Cromer, Christopher A. Vakulskas, et al.. (2024). Transient inhibition of 53BP1 increases the frequency of targeted integration in human hematopoietic stem and progenitor cells. Nature Communications. 15(1). 111–111. 8 indexed citations

Wang, Wenqing, Thomas P. Mathews, Andrew DeVilbiss, et al.. (2024). Failure of metabolic checkpoint control during late-stage granulopoiesis drives neutropenia in reticular dysgenesis. Blood. 144(26). 2718–2734.

Wilkinson, Adam C., Daniel P. Dever, Ron Baik, et al.. (2021). Cas9-AAV6 gene correction of beta-globin in autologous HSCs improves sickle cell disease erythropoiesis in mice. Nature Communications. 12(1). 686–686. 69 indexed citations

Sharma, Rajiv P., Daniel P. Dever, Ciaran M. Lee, et al.. (2021). The TRACE-Seq method tracks recombination alleles and identifies clonal reconstitution dynamics of gene targeted human hematopoietic stem cells. Nature Communications. 12(1). 472–472. 21 indexed citations

Quintana-Bustamante, Óscar, Daniel P. Dever, Rebeca Sánchez‐Domínguez, et al.. (2021). Clinically relevant gene editing in hematopoietic stem cells for the treatment of pyruvate kinase deficiency. Molecular Therapy — Methods & Clinical Development. 22. 237–248. 13 indexed citations

Charlesworth, Carsten T., Daniel P. Dever, Joab Camarena, et al.. (2019). Identification of preexisting adaptive immunity to Cas9 proteins in humans. Nature Medicine. 25(2). 249–254. 665 indexed citations breakdown →

Dever, Daniel P., Joab Camarena, Eric Kildebeck, et al.. (2019). CRISPR/Cas9 Genome Engineering in Engraftable Human Brain-Derived Neural Stem Cells. iScience. 15. 524–535. 34 indexed citations

Vakulskas, Christopher A., Daniel P. Dever, Garrett R. Rettig, et al.. (2018). A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells. Nature Medicine. 24(8). 1216–1224. 541 indexed citations breakdown →

Bak, Rasmus O., Daniel P. Dever, & Matthew H. Porteus. (2018). CRISPR/Cas9 genome editing in human hematopoietic stem cells. Nature Protocols. 13(2). 358–376. 226 indexed citations

10.

Cromer, M. Kyle, Sriram Vaidyanathan, Daniel E. Ryan, et al.. (2018). Global Transcriptional Response to CRISPR/Cas9-AAV6-Based Genome Editing in CD34+ Hematopoietic Stem and Progenitor Cells. Molecular Therapy. 26(10). 2431–2442. 87 indexed citations

11.

Charlesworth, Carsten T., Joab Camarena, M. Kyle Cromer, et al.. (2018). Priming Human Repopulating Hematopoietic Stem and Progenitor Cells for Cas9/sgRNA Gene Targeting. Molecular Therapy — Nucleic Acids. 12. 89–104. 76 indexed citations

12.

Dever, Daniel P., Joab Camarena, Ciaran M. Lee, et al.. (2017). Preclinical Development of HBB Gene Correction in Autologous Hematopoietic Stem and Progenitor Cells to Treat Severe Sickle Cell Disease. Blood. 130. 4620–4620. 4 indexed citations

13.

Dever, Daniel P. & Matthew H. Porteus. (2017). The changing landscape of gene editing in hematopoietic stem cells: a step towards Cas9 clinical translation. Current Opinion in Hematology. 24(6). 481–488. 45 indexed citations

14.

Dever, Daniel P., Rasmus O. Bak, Andreas Reinisch, et al.. (2016). CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells. Nature. 539(7629). 384–389. 641 indexed citations breakdown →

15.

Dever, Daniel P., Bryan D. Thompson, Matthieu Genestine, et al.. (2015). Aryl hydrocarbon receptor deletion in cerebellar granule neuron precursors impairs neurogenesis. Developmental Neurobiology. 76(5). 533–550. 40 indexed citations

16.

Dattel, Andrew R., et al.. (2013). The Relationship between Inattentional Insensitivity of Visual, Tactile, and Olfactory Stimuli. Proceedings of the Human Factors and Ergonomics Society Annual Meeting. 57(1). 853–857. 4 indexed citations

17.

Dattel, Andrew R., et al.. (2012). The Effects of Pointing out Failures of Inattentional Blindness on Performance and Situation Awareness. Proceedings of the Human Factors and Ergonomics Society Annual Meeting. 56(1). 1094–1098. 1 indexed citations

18.

Dever, Daniel P. & Lisa A. Opanashuk. (2012). The Aryl Hydrocarbon Receptor Contributes to the Proliferation of Human Medulloblastoma Cells. Molecular Pharmacology. 81(5). 669–678. 37 indexed citations

19.

Lee, Donna W., Mona Thiruchelvam, Daniel P. Dever, et al.. (2011). Subchronic Polychlorinated Biphenyl (Aroclor 1254) Exposure Produces Oxidative Damage and Neuronal Death of Ventral Midbrain Dopaminergic Systems. Toxicological Sciences. 125(2). 496–508. 42 indexed citations

20.

Collins, Loretta L., et al.. (2008). 2,3,7,8-Tetracholorodibenzo-p-Dioxin Exposure Disrupts Granule Neuron Precursor Maturation in the Developing Mouse Cerebellum. Toxicological Sciences. 103(1). 125–136. 66 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact